Peptide-Major Histocompatibility Complex presenting Cytomegalovirus, Epstein-Barr Virus, and Adenovirus antigens (pMHC (CMV/EBV/AdV))

Peptide-Major Histocompatibility Complex (pMHC) complexes presenting antigens from Cytomegalovirus (CMV), Epstein-Barr Virus (EBV), and Adenovirus (AdV) are the molecular structures recognized by T-cells to identify and eliminate virally infected cells. These complexes consist of viral peptide fragments bound to Major Histocompatibility Complex molecules on the surface of infected cells or professional antigen-presenting cells (Source: UniProt, NIH). In immunocompromised patients, such as those undergoing hematopoietic stem cell or solid organ transplantation, the absence of a robust T-cell response against these specific pMHC targets can lead to life-threatening infections and malignancies like post-transplant lymphoproliferative disorder (Source: PubMed, StatPearls). Therapeutic strategies like virus-specific T-cell (VST) therapies, including tabelecleucel and posoleucel, utilize T-cell receptors (TCRs) that specifically target these viral pMHCs to restore cellular immunity (Source: Atara Biotherapeutics, AlloVir). Upon recognition of the pMHC, the T-cells are activated to release cytotoxic granules, leading to the lysis of the target cell. The efficacy of these therapies is contingent upon the precise matching of Human Leukocyte Antigen (HLA) alleles between the therapeutic T-cells and the patient to ensure proper pMHC binding (Source: Journal of Clinical Oncology).

Other names

Viral peptide-HLA complexesCMV/EBV/AdV pMHCMultivirus-specific pMHCViral antigen-MHC complexpMHC (CMV/EBV/AdV)

T-cell receptor (TCR) mediated recognition of viral peptides presented on MHC molecules, leading to cytotoxic T-lymphocyte (CTL) activation and targeted cell lysis.